China Monogenic Diabetes Registry
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorTianjin Medical University General Hospital
About this trial
This observational study aims to establish a digital registry, screening platform for patients with monogenic diabetes using internet-based and mobile application technologies. The primary objectives are to:
Characterize the genetic landscape of monogenic diabetes in the Chinese population, including pathogenic variants and their distribution
Participants will:
* Enroll in the monogenic diabetes registry via mobile application or web-based platform * Undergo molecular genetic testing to establish a definitive diagnosis
Eligibility criteria
Qualifiers
Diabetes diagnosed before 25 years of age; OR diabetes diagnosed before 35 years of age with ≥1 first-degree relative (parent, sibling, or offspring) diagnosed with diabetes before 40 years of age
Body mass index (BMI) at diagnosis 28 kg/m²
Negative glutamic acid decarboxylase antibody (GAD-Ab)
Disqualifiers
Secondary diabetes
Active malignancy or history of malignant tumor within the past 5 years
Trial design
Treatments tested in this trial
- No Interventions
Treatment groups
5,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov